CN115054697B - 抗-cd19抗体和磷酸肌醇3-激酶抑制剂的组合及其用途 - Google Patents

抗-cd19抗体和磷酸肌醇3-激酶抑制剂的组合及其用途 Download PDF

Info

Publication number
CN115054697B
CN115054697B CN202210502807.XA CN202210502807A CN115054697B CN 115054697 B CN115054697 B CN 115054697B CN 202210502807 A CN202210502807 A CN 202210502807A CN 115054697 B CN115054697 B CN 115054697B
Authority
CN
China
Prior art keywords
ser
lymphoma
leu
pro
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210502807.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN115054697A (zh
Inventor
J·恩德尔
M·温德尔里奇
R·博克斯哈默
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Morphosys AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys AG filed Critical Morphosys AG
Priority to CN202210502807.XA priority Critical patent/CN115054697B/zh
Publication of CN115054697A publication Critical patent/CN115054697A/zh
Application granted granted Critical
Publication of CN115054697B publication Critical patent/CN115054697B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
CN202210502807.XA 2015-08-21 2016-08-18 抗-cd19抗体和磷酸肌醇3-激酶抑制剂的组合及其用途 Active CN115054697B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210502807.XA CN115054697B (zh) 2015-08-21 2016-08-18 抗-cd19抗体和磷酸肌醇3-激酶抑制剂的组合及其用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15181925.7 2015-08-21
EP15181925 2015-08-21
CN202210502807.XA CN115054697B (zh) 2015-08-21 2016-08-18 抗-cd19抗体和磷酸肌醇3-激酶抑制剂的组合及其用途
PCT/EP2016/069571 WO2017032679A1 (en) 2015-08-21 2016-08-18 Combinations and uses thereof
CN201680048061.2A CN107921129B (zh) 2015-08-21 2016-08-18 组合及其用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680048061.2A Division CN107921129B (zh) 2015-08-21 2016-08-18 组合及其用途

Publications (2)

Publication Number Publication Date
CN115054697A CN115054697A (zh) 2022-09-16
CN115054697B true CN115054697B (zh) 2024-06-11

Family

ID=54010888

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210502807.XA Active CN115054697B (zh) 2015-08-21 2016-08-18 抗-cd19抗体和磷酸肌醇3-激酶抑制剂的组合及其用途
CN201680048061.2A Active CN107921129B (zh) 2015-08-21 2016-08-18 组合及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680048061.2A Active CN107921129B (zh) 2015-08-21 2016-08-18 组合及其用途

Country Status (23)

Country Link
US (3) US11224654B2 (enExample)
EP (2) EP3337506B1 (enExample)
JP (4) JP6862422B2 (enExample)
KR (2) KR102786010B1 (enExample)
CN (2) CN115054697B (enExample)
AU (3) AU2016311136B2 (enExample)
CA (1) CA2995738A1 (enExample)
CY (1) CY1124706T1 (enExample)
DK (1) DK3337506T3 (enExample)
ES (1) ES2891336T3 (enExample)
HR (1) HRP20211291T1 (enExample)
HU (1) HUE056408T2 (enExample)
IL (2) IL257345B2 (enExample)
LT (1) LT3337506T (enExample)
MX (2) MX392561B (enExample)
PL (1) PL3337506T3 (enExample)
PT (1) PT3337506T (enExample)
RS (1) RS62260B1 (enExample)
RU (1) RU2767063C2 (enExample)
SI (1) SI3337506T1 (enExample)
SM (1) SMT202100541T1 (enExample)
WO (1) WO2017032679A1 (enExample)
ZA (1) ZA201801052B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115054697B (zh) * 2015-08-21 2024-06-11 莫佛塞斯公司 抗-cd19抗体和磷酸肌醇3-激酶抑制剂的组合及其用途
PT3532098T (pt) 2016-10-28 2021-06-17 Morphosys Ag Combinação de anticorpo anti cd19 com um inibidor bcl-2 e suas utilizações
SMT202300338T1 (it) 2017-05-31 2023-11-13 Morphosys Ag Paradigma di trattamento per un trattamento combinato di anticorpo anti-cd19 e venetoclax
JP7279011B2 (ja) 2017-07-10 2023-05-22 インターナショナル－ドラッグ－ディベロップメント－バイオテック 抗ｃｄ２０抗体または化学療法薬と併用して非フコシル化アポトーシス促進性抗ｃｄ１９抗体を用いるｂ細胞悪性の治療
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
TW202131950A (zh) * 2019-10-31 2021-09-01 德商莫菲西斯公司 依序抗ｃｄ１９療法
TW202241436A (zh) * 2020-11-30 2022-11-01 美商英塞特公司 抗ｃｄ１９抗體及帕薩昔布（ｐａｒｓａｃｌｉｓｉｂ）之組合療法
AU2022419233A1 (en) * 2021-12-22 2024-07-04 Incyte Corporation Treatment paradigm for an anti-cd19 antibody therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103703027A (zh) * 2011-08-16 2014-04-02 莫佛塞斯公司 使用抗cd-19抗体和嘌呤类似物的联合治疗
CN103732252A (zh) * 2011-08-16 2014-04-16 莫佛塞斯公司 使用抗cd-19抗体和氮芥的联合治疗

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0138854B1 (en) 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
NZ522076A (en) 2000-04-25 2005-08-26 Icos Corp Inhibitors of human phosphatidyl-inositol 3-kinase delta
MXPA03002262A (es) 2000-09-18 2003-10-15 Idec Pharma Corp Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b.
JP2005512044A (ja) 2001-12-03 2005-04-28 アブジェニックス・インコーポレーテッド 結合特性に基づく抗体分類
US20080152649A1 (en) * 2002-03-01 2008-06-26 Xencor, Inc. Optimized igf-1r antibodies and methods of using the same
EP1648512A4 (en) 2003-07-31 2009-01-21 Immunomedics Inc ANTI-CD19 ANTIBODIES
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
CN102229609A (zh) 2004-05-13 2011-11-02 艾科斯有限公司 作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮
AU2006262232A1 (en) 2005-06-20 2007-01-04 Medarex, Inc. CD19 antibodies and their uses
JP2009521912A (ja) 2005-12-30 2009-06-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 低減された免疫原性を有する抗ｃｄ１９抗体
SI2059536T1 (sl) * 2006-08-14 2014-06-30 Xencor, Inc. Optimirana protitelesa, ki ciljajo CD19
ATE551071T1 (de) 2006-09-08 2012-04-15 Medimmune Llc Humanisierte anti-cd19-antikörper und ihre verwendung für die behandlung von krebs, transplantationen und autoimmunerkrankungen
EP3392273A1 (en) 2007-05-30 2018-10-24 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
LT2211904T (lt) 2007-10-19 2016-11-25 Seattle Genetics, Inc. Cd19 surišantys agentai ir jų panaudojimas
CA2753158A1 (en) 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
WO2010151341A1 (en) 2009-06-24 2010-12-29 The Feinstein Institute For Medical Research Method for treating chronic lymphocytic leukemia
PL2493503T5 (pl) * 2009-10-27 2021-05-31 Amgen Research (Munich) Gmbh Schemat dawkowania do podawania dwuswoistego przeciwciała CD19xCD3
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
WO2012054748A2 (en) * 2010-10-22 2012-04-26 Seattle Genetics, Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
UY34656A (es) 2012-03-05 2013-10-31 Gilead Calistoga Llc Polimorfos de (s)?2?(1?(9h?purin?6?ilamino)propil)?5?fluor?3?fenilquinazolin?4(3h)?ona, composición y método de preparación
MX375194B (es) 2012-11-01 2025-03-06 Infinity Pharmaceuticals Inc Tratamiento de cánceres utilizando moduladores de las isoformas de pi3 cinasa.
WO2014126928A1 (en) 2013-02-15 2014-08-21 3M Innovative Properties Company System and method for making pleated filter media
CN106794231A (zh) 2014-06-16 2017-05-31 赞科股份有限公司 用于慢性淋巴细胞性白血病（cll）的治疗
SMT201900647T1 (it) 2015-05-26 2020-01-14 Morphosys Ag Combinazione di un anticorpo anti-cd19 e un inibitore della tirosina chinasi di bruton e suoi usi
CN115054697B (zh) 2015-08-21 2024-06-11 莫佛塞斯公司 抗-cd19抗体和磷酸肌醇3-激酶抑制剂的组合及其用途
KR102416144B1 (ko) 2016-05-30 2022-07-04 모르포시스 아게 환자에서 항-cd19 치료법의 치료 이익의 예측 방법
MA45450B1 (fr) 2016-06-27 2021-04-30 Morphosys Ag Formulations d'anticorps anti-cd19
PT3532098T (pt) 2016-10-28 2021-06-17 Morphosys Ag Combinação de anticorpo anti cd19 com um inibidor bcl-2 e suas utilizações
SMT202300338T1 (it) 2017-05-31 2023-11-13 Morphosys Ag Paradigma di trattamento per un trattamento combinato di anticorpo anti-cd19 e venetoclax
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
KR20220007087A (ko) 2019-05-03 2022-01-18 모르포시스 아게 제한된 수의 nk 세포를 갖는 환자에서의 항-cd19 치료제
TW202131950A (zh) 2019-10-31 2021-09-01 德商莫菲西斯公司 依序抗ｃｄ１９療法
DK4051710T3 (da) 2019-10-31 2025-12-15 Incyte Corp Antitumor-kombinationsterapi bestående af anti-cd19-antistof og gamma-delta-t-celler
AU2020376305A1 (en) 2019-10-31 2022-05-12 Incyte Corporation Anti-CD19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
CA3181827A1 (en) 2020-06-22 2021-12-30 Morphosys Ag Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirp?-cd47 innate immune checkpoint
TW202241436A (zh) 2020-11-30 2022-11-01 美商英塞特公司 抗ｃｄ１９抗體及帕薩昔布（ｐａｒｓａｃｌｉｓｉｂ）之組合療法
MX2023006538A (es) 2020-12-04 2023-08-08 Morphosys Ag Terapia combinada de anticuerpo anti cúmulo de diferenciación 19 (cd19).
AU2022419233A1 (en) 2021-12-22 2024-07-04 Incyte Corporation Treatment paradigm for an anti-cd19 antibody therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103703027A (zh) * 2011-08-16 2014-04-02 莫佛塞斯公司 使用抗cd-19抗体和嘌呤类似物的联合治疗
CN103732252A (zh) * 2011-08-16 2014-04-16 莫佛塞斯公司 使用抗cd-19抗体和氮芥的联合治疗

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia:state of the art;Tadeusz Robak;Expert Review of Hematology;第7卷(第6期);第841页摘要、第843页表2、第845页左栏第3段和第851页右栏第4段 *

Also Published As

Publication number Publication date
HK1247122A1 (zh) 2018-09-21
MX392561B (es) 2025-03-24
CN107921129A (zh) 2018-04-17
IL297057B2 (en) 2025-11-01
US11224654B2 (en) 2022-01-18
IL257345A (en) 2018-03-29
RU2767063C2 (ru) 2022-03-16
DK3337506T3 (da) 2021-09-06
US20180228893A1 (en) 2018-08-16
ZA201801052B (en) 2021-05-26
IL257345B (en) 2022-11-01
JP6862422B2 (ja) 2021-04-21
JP2025131697A (ja) 2025-09-09
EP3954388A1 (en) 2022-02-16
WO2017032679A1 (en) 2017-03-02
HRP20211291T1 (hr) 2021-12-10
SMT202100541T1 (it) 2021-11-12
EP3337506A1 (en) 2018-06-27
EP3337506B1 (en) 2021-07-21
ES2891336T3 (es) 2022-01-27
KR20240052084A (ko) 2024-04-22
AU2022202800A1 (en) 2022-05-19
IL257345B2 (en) 2023-03-01
KR20180042335A (ko) 2018-04-25
CN115054697A (zh) 2022-09-16
CA2995738A1 (en) 2017-03-02
NZ739706A (en) 2025-02-28
MX2022006154A (es) 2022-10-07
CY1124706T1 (el) 2022-07-22
RU2018107929A (ru) 2019-09-23
AU2016311136B2 (en) 2022-02-17
RS62260B1 (sr) 2021-09-30
PL3337506T3 (pl) 2022-01-03
JP2021113194A (ja) 2021-08-05
RU2018107929A3 (enExample) 2020-01-14
HUE056408T2 (hu) 2022-02-28
IL297057B1 (en) 2025-07-01
LT3337506T (lt) 2021-10-11
US12194095B2 (en) 2025-01-14
AU2016311136A1 (en) 2018-03-01
JP2018523685A (ja) 2018-08-23
MX2018002241A (es) 2018-03-23
KR102786010B1 (ko) 2025-03-26
CN107921129B (zh) 2022-05-27
AU2022202800B2 (en) 2024-01-04
PT3337506T (pt) 2021-09-24
IL297057A (en) 2022-12-01
SI3337506T1 (sl) 2021-12-31
US20220088197A1 (en) 2022-03-24
JP2023093495A (ja) 2023-07-04
AU2024202109A1 (en) 2024-05-02
US20250195646A1 (en) 2025-06-19
BR112018003263A2 (pt) 2018-09-25

Similar Documents

Publication Publication Date Title
AU2022202796B2 (en) Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereof
AU2022202800B2 (en) Combinations and uses thereof
HK1251152A1 (en) Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
HK40069168A (en) Combinations and uses thereof
HK40023127A (en) Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
HK1247122B (en) Combinations and uses thereof
BR112018003263B1 (pt) Combinação sinérgica

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20250320

Address after: Delaware, USA

Patentee after: INCYTE Corp.

Country or region after: U.S.A.

Address before: Praneger, Germany

Patentee before: MORPHOSYS AG

Country or region before: Germany